Evolutionary Therapy for Rhabdomyosarcoma

Phase: Recruiting

Condition(s): Rhabdomyosarcoma

NCT Number: NCT04388839 Other Study ID Number(s): MCC20339

What Is the Purpose of This Study?

This clinical trial will evaluate four different strategies of chemotherapy schedules in newly diagnosed participants with metastatic fusion positive (alveolar) rhabdomyosarcoma.

Who Can Take Part in This Study?

  • People with new diagnosis of rhabdomyosarcoma with distant metastatic disease and no prior systemic chemotherapy.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04388839

What Will Happen During This Study?

The participant and their physician will choose from:

  • Arm A) a first strike therapy,
  • Arm B) a first strike-second strike (maintenance) therapy,
  • Arm C) an adaptively timed therapy, and
  • Arm D) conventional chemotherapy.
  • Principal Investigator

    Bhuvana A. Setty
    MD

    Hematology & Oncology

    Discover More Research
    Explore additional studies relating to sarcoma and solid tumors